Literature DB >> 2338112

Lack of interaction between disulfiram and alprazolam in alcoholic patients.

B Diquet1, L Gujadhur, D Lamiable, D Warot, H Hayoun, H Choisy.   

Abstract

Certain interactions between disulfiram and benzodiazepines, especially diazepam and chlordiazepoxide, have previously been reported. The influence of disulfiram on the pharmacokinetics of alprazolam, a triazolobenzodiazepine, metabolized by hepatic microsomal oxidation, has been evaluated in 11 chronic alcoholic patients (6 males, 5 females) undergoing treatment for the alcohol withdrawal syndrome. Each patient received alprazolam 2 mg on the first day (control) followed by two weeks of treatment with disulfiram 0.5 g/d, and then further oral dose of alprazolam 2 mg. No significant change was found in any of the kinetic parameters. Thus, a therapeutic dose of disulfiram did not significantly alter the clearance or half-life of alprazolam in chronic alcoholic patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338112     DOI: 10.1007/bf00265976

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  INHIBITION OF DOPAMINE-BETA-HYDROXYLASE BY DISULFIRAM.

Authors:  M GOLDSTEIN; B ANAGNOSTE; E LAUBER; M R MCKEREGHAM
Journal:  Life Sci (1962)       Date:  1964-07

2.  Interaction of disulfiram with benzodiazepines.

Authors:  S M MacLeod; E M Sellers; H G Giles; B J Billings; P R Martin; D J Greenblatt; J A Marshman
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

3.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

4.  Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.

Authors:  R B Smith; P R Gwilt; C E Wright
Journal:  Clin Pharm       Date:  1983 Mar-Apr

5.  The rapid reduction of disulfiram in blood and plasma.

Authors:  J Cobby; M Mayersohn; S Selliah
Journal:  J Pharmacol Exp Ther       Date:  1977-09       Impact factor: 4.030

6.  Alprazolam pharmacokinetics in alcoholic liver disease.

Authors:  R P Juhl; D H Van Thiel; L W Dittert; R B Smith
Journal:  J Clin Pharmacol       Date:  1984 Feb-Mar       Impact factor: 3.126

7.  The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R B Smith; R I Shader
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

8.  Double-blind comparison of alprazolam and diazepam for subchronic withdrawal from alcohol.

Authors:  I S Kolin; O I Linet
Journal:  J Clin Psychiatry       Date:  1981-04       Impact factor: 4.384

9.  Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.

Authors:  R B Smith; P D Kroboth; J T Vanderlugt; J P Phillips; R P Juhl
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Cimetidine spares the glucuronidation of lorazepam and oxazepam.

Authors:  R V Patwardhan; G W Yarborough; P V Desmond; R F Johnson; S Schenker; K V Speeg
Journal:  Gastroenterology       Date:  1980-11       Impact factor: 22.682

View more
  3 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

2.  Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.

Authors:  Reginald F Frye; Robert A Branch
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.